Same Indication

Pembrolizumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D

Pembrolizumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D: Overview

This comparison examines the pharmacological differences between Pembrolizumab and Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Pembrolizumab — 26 days.

Chemical Properties

Type: Pembrolizumab — Antibody; Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D — Vaccine component.